Not Yet Recruiting
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
NCT07581509
- Conditions
- Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings), Melanoma, Neoplasms, +10 more
- Locations
-
Not specified